Evidence map›Paper›PMID 42362558›Full record

ArticleNPJ Parkinson's disease2026

A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National Cohort.

Klaus Berger, André Karch, Christina M Lill, Tom L Berger, Ulrich Mueller, Michael Bartl, Brit Mollenhauer, Beate Fischer, Karin B Michels, Philipp T Meyer and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Klaus BergerInstitute of Epidemiology and Social Medicine, University of, Münster, Germany. bergerk@uni-muenster.de.
André KarchInstitute of Epidemiology and Social Medicine, University of, Münster, Germany.
Christina M LillInstitute of Epidemiology and Social Medicine, University of, Münster, Germany.
Tom L BergerInstitute of Epidemiology and Social Medicine, University of, Münster, Germany.
Ulrich MuellerInstitute for Health Services Research and Clinical Epidemiology, Medical School, Philipps-University, Marburg, Germany.
Michael BartlDepartment of Neurology, University Medical Center, Goettingen, Germany.
Brit MollenhauerDepartment of Neurology, University Medical Center, Goettingen, Germany.
Beate FischerInstitute for Epidemiology and Preventive Medicine, University of Regensburg, Bavaria, Germany.
Karin B MichelsInstitute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Philipp T MeyerDepartment of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Verena A KatzkeDivision of Cancer Epidemiology C020, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jara SabinDivision of Cancer Epidemiology C020, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stefan N WillichInstitute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Thomas KeilInstitute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Stefanie CastellDepartment for Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany.
Anja M HauriDepartment for Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Tamara SchikowskiIUF-Leibniz Institut für umweltmedizinische Forschung, Düsseldorf, Germany.
Oliver RiedelLeibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.
Tobias PischonMolecular Epidemiology Research Group, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Ilais Moreno VelasquezMolecular Epidemiology Research Group, Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Sebastian HeinzelDepartment of Neurology, Kiel University, University Medical Centre Schleswig-Holstein, Kiel, Germany.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Annette PetersInstitute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Munich, Germany.
Rafael MikolajczykInstitute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Center for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle(Saale), Germany.
Theresa HerrmannInstitute for Medical Epidemiology, Biometrics, and Informatics, Interdisciplinary Center for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle(Saale), Germany.
Claudia TrenkwalderParacelsus-Elena Klinik, Center for Parkinsonism and Movement Disorders, Kassel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A strong increase in the prevalence and deaths of Parkinson's disease (PD) has been reported over the last three decades. Ageing societies, genetic and environmental factors and access to health care contribute to these increases. Using data of the German National Cohort (NAKO) PD classifications based on self-report, claims data and a brief medication based algorithm to increase validity in the absence of neurologic examinations, were compared and the PD incidence, selected non-motor symptoms, functions and vital status were analysed. The algorithm based PD prevalence among 205.000 participants was 0.13% but it was 2.5-fold higher in claims data. Self-reported PD incidence was 0.13% over a median of 4.8 years follow-up, but cases had a 4-fold higher mortality, worse emotional, motoric and olfactory functions and higher prevalences of diabetes, obesity, depression and anxiety. The algorithm based PD prevalence and the mortality risk was similar to considerable older population studies from Europe.

Identifiers

PMID42362558
PMCPMC13309536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.